MYELOABLATIVE DOSES OF BUSULFAN AND FLUDARABINE AS CONDITIONING FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN NON-HODGKIN'S LYMPHOMA

被引：1
|
作者：
Figueroa, J. [1 ]
Perkins, J. [1 ]
Anassetti, C. [1 ]
Tomblyn, M. [1 ]
Field, T. [1 ]
Fernandez, H. [1 ]
Ochoa, J. [1 ]
Perez, L. [1 ]
Alsina, M. [1 ]
Locke, F. [1 ]
Nishihori, T. [1 ]
Pidala, J. [1 ]
Ayala, E. [1 ]
机构：
[1] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2012年 / 18卷 / 02期
关键词：
D O I：
10.1016/j.bbmt.2011.12.240
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
252
引用
收藏
页码：S297 / S297
页数：1
相关论文
共 50 条
  • [31] STEM CELL TRANSPLANTATION FOR NON-HODGKIN'S LYMPHOMA (NHL)
    De Souza, Carmino
    LEUKEMIA RESEARCH, 2017, 61 : S11 - S12
  • [32] Allogeneic stem cell transplantation for lymphoma: role of conditioning with treosulfan and fludarabine
    Niittyvuopio, R.
    Heiskanen, J.
    Lindstrom, V.
    Juvonen, E.
    Nihtinen, A.
    Uotinen, H.
    Ruutu, T.
    Volin, L.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S426 - S427
  • [33] Blood stem cell transplantation in non-Hodgkin's lymphoma
    Bishop, MR
    Kessinger, A
    CANCER INVESTIGATION, 1997, 15 (02) : 138 - 142
  • [34] Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients
    M Iravani
    M R Evazi
    S A Mousavi
    A R Shamshiri
    M Tavakoli
    A Ashouri
    S Samiee
    B Chahardovali
    K Alimoghaddam
    S H Ghaffari
    A Ghavamzadeh
    Bone Marrow Transplantation, 2007, 40 : 105 - 110
  • [35] Autologous or allogeneic hematopoietic cell transplantation for non-Hodgkin's lymphoma?
    Blume, KG
    ANNALS OF HEMATOLOGY, 2002, 81 : S9 - S11
  • [36] Allogeneic stem cell transplantation for the non-Hodgkin's lymphomas and Hodgkin's disease
    Hale, GA
    Phillips, GL
    CANCER TREATMENT REVIEWS, 2000, 26 (06) : 411 - 427
  • [37] Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning
    Joseph, Jacinth
    Srour, Samer A.
    Milton, Denai R.
    Ramdial, Jeremy L.
    Saini, Neeraj Y.
    Olson, Amanda L.
    Bashir, Qaiser
    Oran, Betul
    Alousi, Amin M.
    Hosing, Chitra
    Qazilbash, Muzaffar H.
    Kebriaei, Partow
    Shpall, Elizabeth J.
    Champlin, Richard E.
    Popat, Uday R.
    TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (12): : 770e1 - 770e6
  • [38] Reduced-intensity conditioning allogeneic stem cell transplantation for patients with refractory or relapsed non-Hodgkin lymphoma
    De Lavallade, H.
    Bouabdallah, R.
    Faucher, C.
    Furst, S.
    El Cheikh, J.
    Vey, N.
    Stoppa, A. M.
    Sainty, D.
    Arnoulet, C.
    Xerri, L.
    Cassier, P.
    Gastaut, J. A.
    Blaise, D.
    Mohty, M.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S149 - S149
  • [39] The role of rituximab in autologous and allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma
    Naparstek E.
    Current Hematologic Malignancy Reports, 2006, 1 (4) : 220 - 229
  • [40] Reduced intensity allogeneic stem cell transplantation for low grade non-Hodgkin's lymphoma
    Morris, EC
    Mackinnon, S
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2005, 18 (01) : 129 - 142
12345